KRAS 测试的全球市场 - 市场规模（依细分市场）、占有率、监管、偿付、预测（~2033年）

本报告研究和分析了全球 KRAS 测试市场，提供了有关主要参与者、市场占有率、主要趋势、创新产品和技术以及竞争格局的资讯。

市场模型的主要内容如下。

已上市的 KRAS 测试和不断变化的竞争格局

• 对主要产业趋势的考察
• KRAS 检测市场年收入与市场前景（依细分市场）（2015-2033年）
• 有关单位数量、平均售价和市场价值的市场级资料

全球、区域和国家层面的特定市场考察

• 依地区细分全球趋势的特定市场定性资讯和国家考察
• KRAS检测市场的SWOT分析
• KRAS 测试市场竞争动态的考察与趋势

掌握包括医疗保健系统概述真实情况，促进市场了解。市场进入部分还提供有关偿付政策和监管环境的讯息，能够更深入地研究市场动态。

• 各国医疗保健系统概览
• 依国家/地区划分的偿付政策
• 各国医疗科技监理状况

目标公司

• Roche Diagnostics International Ltd + Foundation Medicine Inc
• Qiagen NV
• Agilent Technologies Inc
• Illumina Inc
• Thermo Fisher Scientific Inc
• Abbott Laboratories
• NimaGen BV
• Agena Bioscience Inc
• New England Biolabs Inc
• Amoy Diagnostics Co Ltd
• HLB PanaGene Co Ltd
• EntroGen, Inc
• Sysmex Inostics GmbH
• Biocartis Group NV
• 其他

KRAS Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.

Kirsten Rat Sarcoma (KRAS) is a downstream signaling molecule in the EGFR cellular pathway with roles in cell growth and proliferation.KRAS gene tests are carried out to detect gene mutations in patient tissue samples; the outcome of which may guide therapies to treat various cancers including colorectal cancer, certain lung cancers and some leukemias.

There are no clinically approved therapies that target KRAS. However, its mutational status serves as an indication for response to approved anti-EGFR receptor antibodies in CRC and Tyrosine Kinase Inhibitors (TKIs) in NSCLC.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed KRAS Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total KRAS Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for KRAS Tests market.
• Competitive dynamics insights and trends provided for KRAS Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Roche Diagnostics International Ltd + Foundation Medicine Inc, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV, Agena Bioscience Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, HLB PanaGene Co Ltd, EntroGen, Inc, Sysmex Inostics GmbH, Biocartis Group NV, and others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the KRAS Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving KRAS Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the KRAS Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific KRAS Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.